MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

Search

Jazz Pharmaceuticals PLC

Closed

SectorHealthcare

112.42 0.73

Overview

Share price change

24h

Current

Min

109.16

Max

112.6

Key metrics

By Trading Economics

Income

-284M

-93M

Sales

-190M

898M

P/E

Sector Avg

14.62

39.564

Profit margin

-10.307

Employees

2,800

EBITDA

-275M

109M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+61.86% upside

Dividends

By Dow Jones

Next Earnings

30 Jul 2025

Market Stats

By TradingEconomics

Market Cap

-776M

6.6B

Previous open

111.69

Previous close

112.42

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Jazz Pharmaceuticals PLC Chart

Past performance is not a reliable indicator of future results.

Related News

21 Nov 2024, 14:45 UTC

Major Market Movers

Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK

31 Oct 2024, 15:29 UTC

Major Market Movers

Avadel Pharma Shares Rise on Favorable Ruling for FDA in Lumryz Litigation

Peer Comparison

Price change

Jazz Pharmaceuticals PLC Forecast

Price Target

By TipRanks

61.86% upside

12 Months Forecast

Average 176.64 USD  61.86%

High 230 USD

Low 121 USD

Based on 14 Wall Street analysts offering 12 month price targets forJazz Pharmaceuticals PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

13

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

N/A / 111.22Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$